Search clinical trials for: UFUR and Iressa

Total 269149 results

Taipei Veterans General Hospital, Taiwan

Completed

UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer

Non-Small-Cell Lung Cancer

Taiwan
Neurocenter of Southern Switzerland
Penn State University; Ente Ospedaliero Cantonale, Bellinzona; Parkinson Schweiz

Completed

Sleep, Awake & Move - Part II (SA&M-II)

Idiopathic Parkinson's Disease

Switzerland
AstraZeneca

Completed

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Neoplasms, Squamous Cell

United States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
NYU Langone Health
National Heart, Lung, and Blood Institute (NHLBI); Duke University; National...

Withdrawn

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B (RADAR-B)

End Stage Renal Disease

United States
Chang Gung Memorial Hospital

Unknown

Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+

Squamous Cell Carcinoma of Oral Cavity

Taiwan
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
Changhai Hospital

Completed

An RCT to Compare Early Continence Recovery After RARP With or Without Sustainable Functional Urethral Reconstruction

Urinary Incontinence | Prostate Cancer

China
Chang Gung Memorial Hospital

Completed

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Adverse Reaction to Drug | Vascular Endothelial Growth Factor Overexpression

Taiwan
Stanford University
AstraZeneca; Ligand Pharmaceuticals

Completed

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Lung Cancer

United States
Mackay Memorial Hospital

Unknown

Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

Taiwan
AstraZeneca

Completed

IRESSA™ (Gefitinib) in Breast Cancer Patients

Breast Cancer
Thomas Kuendig

Completed

A Pilot Study for the Determination of Allergenicity of Cat Dander Samples Obtained by Different Methods

Cat Dander Allergy

Switzerland
Kaohsiung Medical University Chung-Ho Memorial...

Active, not recruiting

Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection

Stage III Colon Cancer

Taiwan
Hunan Kelun Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions

Bioequivalence Study
Hunan Kelun Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Gefitinib Tablets Under Fed Conditions

Healthy
National Taiwan University Hospital

Completed

Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Taiwan
China National Center for Cardiovascular Diseases

Not yet recruiting

Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Coronary Artery Lesions (FUNCTION)

Coronary Artery Stenosis
ZhuGuangYing
Zhejiang Cancer Hospital; 307 Hospital of PLA; Fudan University; Cancer Institute... and other collaborators

Unknown

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
National Cancer Centre, Singapore

Completed

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery (PROGRESS)

Non-small Cell Lung Cancer

Singapore
Peking University Cancer Hospital & Institute

Unknown

Blood Detection of EGFR Mutation For Iressa Treatment (Benefit)

Lung Adenocarcinoma

China
Ohio State University
University of North Carolina, Chapel Hill

Completed

Continence Pessary Versus Disposable Intravaginal Device Trial

Female Stress Incontinence

United States
Guangdong Association of Clinical Trials

Completed

Third-line Treatment of Gefitinib in NSCLC Patients

Non Small Cell Lung Cancer

China
Seoul Veterans Hospital

Unknown

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy (SIIS)

Squamous Cell Carcinoma of Bronchus

Korea, Republic of
AstraZeneca

Completed

Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

Locally Advanced Prostate Cancer

Norway
University of Chicago

Completed

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Head and Neck Cancer

United States
University of Chicago
AstraZeneca

Completed

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States
Asan Medical Center
AstraZeneca

Unknown

First Line Gefitinib by FDG-PET Metabolic Response

Non-small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic (AGUS)

Tumors

United States
AstraZeneca

Approved for marketing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Non Small Cell Lung Cancer | Cancer of the Head and Neck

Poland, Germany, Hungary, United Kingdom
University Health Network, Toronto
AstraZeneca

Completed

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

LUNG CANCER

Canada
AstraZeneca

Completed

Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) (INFORM)

Non-small Cell Lung Cancer (NSCLC)

China
Tianjin Medical University Cancer Institute and...

Suspended

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
AstraZeneca

Terminated

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Non Small Cell Lung Carcinoma

Italy
Samsung Medical Center

Unknown

Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Pulmonary Cancer

Korea, Republic of
Tan Tock Seng Hospital
AstraZeneca; Singapore Cancer Syndicate.

Unknown

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Liver Cancer

Singapore
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
Shanghai Chest Hospital

Unknown

Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases) (EGFR)

Non-Small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China
Indiana University School of Medicine
AstraZeneca

Terminated

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR (IUCRO-0021)

Refractory Germ Cell Tumors Expressing EGRF

United States
AstraZeneca

Completed

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

Mesothelioma
AstraZeneca

Terminated

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

Brain Neoplasms | Non Small Cell Lung Cancer

Italy
Guangdong Provincial People's Hospital

Unknown

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastasis
David M. Jackman, MD
Massachusetts General Hospital; AstraZeneca

Completed

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Non-Small Cell Lung Cancer

United States
AstraZeneca

Completed

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment (ICARUS)

Lung Cancer

Italy
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
Chonnam National University Hospital
AstraZeneca

Completed

Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC) (ReGaiN)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
AstraZeneca

Completed

Trial of Iressa in Prostate Cancer Patients

Prostate Cancer

Canada
University Hospital of Crete

Completed

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Breast Cancer

Greece
National Taiwan University Hospital

Completed

Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Taiwan
Sunshine Lake Pharma Co., Ltd.

Active, not recruiting

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Non-small Cell Lung Cancer

China

Search clinical trials for: UFUR and Iressa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations